Skip to main content

Weiner David B.'s Form 4 filing

Inovio Pharmaceuticals, Inc.INO · filed Feb 28, 2023

Accession no.
0001055726-23-000004
Filed
Feb 28, 2023
Trade date
Feb 26-27, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market sales total $14.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Weiner David B.CIK 0001669080Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 26, 2023Common StockMOption exerciseAcquired+11,667–F1–904,292Direct
Feb 26, 2023Common StockMOption exerciseAcquired+11,667–F2–915,959Direct
Feb 27, 2023Common StockSSaleDisposed−11,668$1.28−$14,935.04904,291Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 26, 2023Common StockMOption exerciseDisposed−11,667$0.00$011,666Direct
Feb 26, 2023Common StockMOption exerciseDisposed−11,667$0.00$023,333Direct
Feb 27, 2023Common StockAGrant or awardAcquired+60,000$0.00$060,000Direct
Feb 27, 2023Common StockAGrant or awardAcquired+35,000$0.00$035,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2021, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2022; 11,667 shares vested on February 26, 2023; and 11,666 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Referenced by the price of 1 transaction in Table I.

F2

Each restricted stock unit represents a contingent right to receive one share of common stock. On February 26, 2022, the reporting person was granted 35,000 restricted stock units, vesting as follows: 11,667 shares vested on February 26, 2023; 11,667 shares will vest on February 26, 2024; and 11,666 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)